Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Stands Alone As It Completes Novartis Spinoff

Industry Giant Enters ‘New Era’ As An Independent Company After Long-Awaited Separation

Executive Summary

Sandoz has heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” after completing its long journey towards independence by separating from former parent company Novartis.

You may also be interested in...



Sandoz Agrees $265m Settlement To Resolve US Pricing Litigation

Sandoz has agreed a $265m settlement in the US to resolve generic pricing antitrust class action litigation with direct purchaser plaintiffs, as part of a deal that contains no admission of wrongdoing on the part of the generics giant.

A Year Of Change: Sandoz Completes A Transformational 2023

An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.

Industry Leaderboard Gains And Dips Were Still Marked By COVID-19

Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel